Notice of Results
REDX PHARMA PLC
("Redx" or "the Company")
Notice of Results
Alderley Park, 31 October 2018 Redx (AIM: REDX), the drug development company focused on cancer and fibrosis, will announce its preliminary results for the year ended 30 September 2018 on Monday 19 November 2018.
For further information, please contact:
|
Redx Pharma Plc |
T: +44 1625 469 920 |
|
Lisa Anson, Chief Executive Officer |
|
|
|
|
|
Cantor Fitzgerald Europe (Nominated Advisor & Broker) |
T: +44 20 7894 7000 |
|
Phil Davies |
|
|
|
|
|
WG Partners LLP (Joint Broker) |
T: +44 20 3705 9330 |
|
Claes Spång/ Chris Lee/ David Wilson |
|
|
|
|
|
FTI Consulting |
T: +44 20 3727 1000 |
|
Simon Conway/Stephanie Cuthbert |
|
About Redx Pharma Plc
Redx is a UK biotechnology company whose shares are traded on AIM (AIM:REDX). Redx's vision is to become a leading biotech focused on the development of novel precision medicines that have the potential to transform treatment in oncology and fibrotic diseases.
If you would like to sign up to regular alerts from Redx Pharma, please follow this link https://www.redxpharma.com/investors/email-alerts/.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
COMPANIES COVERED:
Latest directors dealings
- 2 days ago FRP Advisory Group
- 2 days ago Marks Electrical Group
- 2 days ago CLS Holdings
- 2 days ago QinetiQ Group
- 2 days ago Spectris